GlassScriptPhysician profile
Tauni R Carter
NPI 1811292170
$4,833.46
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,493 · 2022: $942 · 2023: $1,335 · 2024: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $859.63 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $569.97 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Sanofi-Aventis U.S. LLC | $365.89 | 2021-2023 | |
| Amgen INC. | $363.67 | 2021-2024 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $338.24 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.44 | 2021-2024 | Jardiance |
| Abbott Laboratories | $225.40 | 2021-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $171.56 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $169.66 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $140.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $122.37 | 2022-2024 | |
| Dexcom, INC. | $117.41 | 2021-2024 | Dexcom G6 Transmitter |
| Vistapharm, INC. | $114.32 | 2021 | |
| Alexion Pharmaceuticals, INC. | $112.77 | 2021-2024 | Strensiq |
| Zealand Pharma US, INC. | $105.57 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $102.90 | 2021-2024 | Minimed 780g, Intellis Adaptivestim |
| Chiasma, INC. | $88.64 | 2021 | |
| Horizon Therapeutics Plc | $70.42 | 2022-2023 | Tepezza |
| Amarin Pharma, INC. | $66.15 | 2021-2022 | |
| Esperion Therapeutics, INC. | $64.23 | 2021-2024 | Nexletol |
| Mannkind Corporation | $59.47 | 2021-2022 | |
| Radius Health, INC. | $55.24 | 2021-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $52.86 | 2021-2022 | |
| Astellas Pharma US INC | $50.62 | 2023 | Veozah |
| Lifescan, INC. | $47.51 | 2021-2022 | |
| Pfizer INC. | $34.84 | 2021-2023 | |
| Echosens North America, INC. | $29.27 | 2024 | Fibroscan |
| Recordati_rare_diseases_inc. | $24.74 | 2021 | |
| Kyowa Kirin, INC. | $20.63 | 2024 | Crysvita |
| Tandem Diabetes Care, INC. | $19.46 | 2021 | |
| Abbvie INC. | $14.55 | 2021 | |
| Alfasigma USA, INC. | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tauni Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.